Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07319-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Harlan Pittell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Flatiron Health, 233 Spring St, New York, NY, 10013, USA. harlan.pittell@flatiron.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Healthcare Disparities. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Flatiron Health.
Abstract (Originalsprache)
Purpose
Racialized economic segregation, a form of structural racism, may drive persistent inequities among patients with breast cancer. We examined whether a composite area-level index of racialized economic segregation was associated with real-world treatment and survival in metastatic breast cancer (mBC).
Methods
We conducted a retrospective cohort study among adult women with mBC using a US nationwide electronic health record-derived de-identified database (2011–2022). Population-weighted quintiles of the index of concentration at the extremes were estimated using census tract data. To identify inequities in time to treatment initiation (TTI) and overall survival (OS), we employed Kaplan–Meier methods and estimated hazard ratios (HR) adjusted for clinical factors.
Results
The cohort included 27,459 patients. Compared with patients from the most privileged areas, those from the least privileged areas were disproportionately Black (36.9% vs. 2.6%) or Latinx (13.2% vs. 2.6%) and increasingly diagnosed with de novo mBC (33.6% vs. 28.9%). Those from the least privileged areas had longer median TTI than those from the most privileged areas (38 vs 31 days) and shorter median OS (29.7 vs 39.2 months). Multivariable-adjusted HR indicated less timely treatment initiation (HR 0.87, 95% CI 0.83, 0.91, p < 0.01) and worse OS (HR 1.19, 95% CI 1.13, 1.25, p < 0.01) among those from the least privileged areas compared to the most privileged areas.
Conclusion
Racialized economic segregation is a social determinant of health associated with treatment and survival inequities in mBC. Public investments directly addressing racialized economic segregation and other forms of structural racism are needed to reduce inequities in cancer care and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Flatiron Health, 233 Spring St, New York, NY, 10013, USA. harlan.pittell@flatiron.com.
- Program on Medicines and Public Health, University of Southern California School of Pharmacy, Los Angeles, USA.
- Flatiron Health, 233 Spring St, New York, NY, 10013, USA.
- Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Division of Health Policy and Management, Berkeley School of Public Health, University of California, Berkeley, USA.
Förderung
- NCI NIH HHS
- Flatiron Health
Zitieren
APA
Pittell, H., Calip, G. S., Pierre, A., Ryals, C. A., & Guadamuz, J. S. (2024). Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07319-5
Vancouver
Pittell H, Calip GS, Pierre A, Ryals CA, Guadamuz JS. Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07319-5
BibTeX
@article{Pittell2024,
author = {Pittell, Harlan and Calip, Gregory S and Pierre, Amy and Ryals, Cleo A and Guadamuz, Jenny S},
title = {Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07319-5}
}
EUVIMED